Home > News > Pharmaceutical News
Posted on Apr 29, 12:15PM | IBNS
Pittsburgh/Mumbai, Apr 29 : Mylan Laboratories Limited, the Indian subsidiary of Mylan Inc. (Nasdaq: MYL), Saturday announced that it has entered into a partnership with the United Nation's Millennium Development Goals Health Alliance (MDGHA) and the Clinton Health Access Initiative (CHAI) to fight childhood deaths caused by diarrhea.
According to a recent United Nations study, India has the highest number of childhood fatalities per year caused by diarrhea. These unnecessary deaths primarily are attributed to the lack of access to treatments like oral rehydration solution (ORS) and zinc.
A recent World Health Organization report estimates that diarrhea is the second leading cause of death globally among children under five.
At a conference conducted in Mumbai on Saturday to discuss how public-private partnerships can be mobilized to advance the health of women and children in India, Mylan announced that it would develop and expand access to ORS and zinc for needy children across the country.
Anirudh Deshpande, Senior Vice President for Business Development of Mylan Laboratories in India, said: "This is a tragic, heartbreaking and avoidable situation that largely can be addressed if these children simply get the treatments they need."
Mylan's wide range of ARV products includes 13 active pharmaceutical ingredients (API) and 42 first- and second-line finished doses, nine of which are pediatric products.
The company claimed its emphasis on producing affordable ARV products has helped to drive down the average annual cost per patient of effective therapies.